These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11054093)

  • 41. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.
    Nisbet-Brown E; Olivieri NF; Giardina PJ; Grady RW; Neufeld EJ; Séchaud R; Krebs-Brown AJ; Anderson JR; Alberti D; Sizer KC; Nathan DG
    Lancet; 2003 May; 361(9369):1597-602. PubMed ID: 12747879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.
    Al-Rousan RM; Manzoor K; Paturi S; Arvapalli RK; Laurino JP; Darnon L; Walker EM; Blough ER
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):117-25. PubMed ID: 21593444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
    Yusuf B; McPhedran P; Brewster UC
    Am J Kidney Dis; 2008 Sep; 52(3):587-90. PubMed ID: 18534729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron mobilization using chelation and phlebotomy.
    Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
    Quarta A; Melpignano A; Quarta G
    Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F; Phatak P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic hemosiderosis in common marmosets, Callithrix jacchus: effect of diet on incidence and severity.
    Miller GF; Barnard DE; Woodward RA; Flynn BM; Bulte JW
    Lab Anim Sci; 1997 Apr; 47(2):138-42. PubMed ID: 9150491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
    Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
    Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deferasirox.
    Stumpf JL
    Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
    Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
    Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
    Bergeron RJ; Wiegand J; McManis JS; Bussenius J; Smith RE; Weimar WR
    J Med Chem; 2003 Apr; 46(8):1470-7. PubMed ID: 12672247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum.
    Goudeau C; Loyevsky M; Kassim OO; Gordeuk VR; Nick H
    Br J Haematol; 2001 Dec; 115(4):918-23. PubMed ID: 11843826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients.
    Yii E; Doery JC; Kaplan Z; Kerr PG
    Nephrology (Carlton); 2018 Sep; 23(9):887-889. PubMed ID: 29663590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.